Sunshine Heart to Attend Upcoming Investor Conferences

Sunshine Heart to Attend Upcoming Investor Conferences 
EDEN PRAIRIE, MN and SYDNEY, AUSTRALIA -- (Marketwire) -- 02/26/13 --
 Sunshine Heart, Inc. (NASDAQ: SSH) (ASX: SHC) today announced that
the company is scheduled to attend the following upcoming investor

--  Lazard Capital Markets Medical Technology Snowbird Conference in Salt
    Lake City, UT
    --  Wednesday, February 27th (one-on-ones only) at the Cliff Lodge
        Snowbird Ski and Summer Resort
--  Cowen and Company 33rdAnnual Healthcare Conference in Boston, MA
    --  Presentation: Monday, March 4th at 2:50p EST at the Boston
        Marriott Copley Place
    --  Presenting: Dave Rosa, Chief Executive Officer

About Sunshine(R) Heart 
 Sunshine Heart, Inc. (NASDAQ: SSH) (ASX: SHC)
is an early-stage global medical device company committed to the
commercialization of the C-Pulse System, an implantable, non-blood
contacting, heart assist therapy for the treatment of moderate to
severe heart failure. The C-Pulse System can be implanted using a
minimally invasive procedure and is designed to relieve the symptoms
of heart failure through the use of counter-pulsation technology,
which enables an increase in cardiac output, an increase in coronary
blood flow and a reduction in the heart's pumping load. Sunshine
Heart has completed an approved U.S. Food and Drug Administration
(FDA) feasibility clinical trial of the C-Pulse System and presented
the results in November 2011. In March, 2012, the FDA notified the
Company that it could move forward with an investigational device
exemption (IDE) application. Sunshine Heart received unconditional
approval from the FDA in November 2012 to initiate its pivotal trial.
In July 2012 Sunshine Heart received CE Mark approval for its C-Pulse
System in Europe. Sunshine Heart is a Delaware corporation
headquartered in Minneapolis with a subsidiary presence in Australia.
The Company has been listed on the Australian Securities Exchange
(ASX) since September 2004 and on the NASDAQ Capital Market since
February 2012. For more information, please visit 
About the C-Pulse(R) Heart Assist System 
 The C-Pulse Heart Assist
System, or C-Pulse System, an investigational device in the United
States, Canada and countries that do not recognize the CE Mark
approval, utilizes the scientific principles of intra-aortic balloon
counter-pulsation applied in an extra-aortic approach to assist the
left ventricle by reducing the workload required to pump blood
throughout the body, while increasing blood flow to the coronary
arteries. Operating outside the patient's bloodstream, the
extra-aortic approach of the C-Pulse technology offers greater
flexibility, allowing patients to safely disconnect to have intervals
of freedom to perform certain activities such as showering. The
C-Pulse System may help maintain the patient's current condition and,
in some cases, reverse the heart failure process, thereby potentially
preventing the need for later stage heart failure therapies, such as
left ventricular assist devices (LVADs), artificial hearts or
Caution: Investigational device, limited by Federal (or United
States) Law to Investigational use. 
Forward-Looking Statements  
Certain statements in this release are forward-looking statements
that are based on management's beliefs, assumptions and expectations
and information currently available to management. All statements
that address future operating performance, events or developments
that we expect or anticipate will occur in the future are
forward-looking statements, including without limitation, our
expectations with respect to future clinical trial activities and
results including patient enrollment in trials. These forward-looking
statements are subject to numerous risks and uncertainties, including
without limitation, the possibility that our clinical trials do not
meet their enrollment goals, meet their end-points or otherwise fail,
that regulatory authorities do not accept our application or approve
the marketing of the C-Pulse System, the possibility we may be unable
to raise the funds necessary for the development and
commercialization of our products, that we may not be able to
commercialize our products successfully in the EU and the other risk
factors described under the caption "Risk Factors" and elsewhere in
our filings with the U.S. Securities and Exchange Commission and ASX.
You should not place undue reliance on forward-looking statements
because they speak only as of the date when made and may turn out to
be inaccurate. We do not assume any obligation to publicly update or
revise any forward-looking statements, whether as a result of new
information, future events or otherwise. We may not actually achieve
the plans, projections or expectations disclosed in forward-looking
statements, and actual results, developments or events could differ
materially from those disclosed in the forward-looking statements. 
For further information, please contact:  
Laura Forman
Blueprint Life Science Group 
T: +1-415-375-3340 
Jeff Mathiesen
Chief Financial Officer
Sunshine Heart, Inc.
T: +1-952-345-4200 
Press spacebar to pause and continue. Press esc to stop.